BiomodaFiles New Patent Application To Optimize CyPath® Assay

Published: Nov 03, 2011

ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) ( filed an application for a new U.S. Patent that refines the use of fluorescent microscopy to increase the accuracy, sensitivity and specificity of the CyPath® diagnostic assay for lung cancer.

Back to news